Mi­rati's KRAS drug looks like the ear­ly fa­vorite in colon can­cer with new da­ta, putting the pres­sure square on Am­gen

With Am­gen al­ready pro­vid­ing proof-of-con­cept for KRAS in­hibitors with its so­tora­sib, Mi­rati Ther­a­peu­tics is piec­ing to­geth­er a fol­low-up ef­fort in lung can­cer with da­ta it thinks are su­pe­ri­or. But in colon can­cer, where so­lo so­tora­sib has turned in a dud, Mi­rati may now have a strong case for su­pe­ri­or­i­ty.

Mi­rati’s ada­gra­sib, dosed so­lo or in com­bi­na­tion with chemother­a­py ce­tux­imab, showed nu­mer­i­cal­ly high­er re­sponse rates than so­tora­sib so­lo and as part of a com­bi­na­tion study in a sim­i­lar pa­tient pop­u­la­tion al­so re­vealed this week at #ES­MO21. Mi­rati’s da­ta were pre­sent­ed as part of a co­hort up­date from the Phase II KRYS­TAL-1 study test­ing ada­gra­sib in a range of sol­id tu­mors har­bor­ing the KRAS-G12C mu­ta­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.